This list of protocols
for selected new antitumor agents is compiled for your convenience.
Anti-Angiogenesis
Agents
Phase II
RUH-SSH-190-0698,
NCI-V98-1425 Randomized
Study of Three Plant Phenolic Compounds Versus Sulindac (Part A) or Curcumin
(Part B) in Prevention of Colon Cancer
Chairperson: Steven J. Shiff. Telephone: 212-327-7458. Lead organization: Rockefeller
University Hospital. Age range: 18 and over.
RTOG-1024
Phase I/II Study of Marimastat and External Beam Radiation in Patients With
Supratentorial Glioblastoma Multiforme or Gliosarcoma
Chairperson: Walter John Curran, Jr. Telephone: 215-955-6700. Lead organization:
Radiation Therapy Oncology Group. Age range: no age specified.
NCI-98-C-0159,
NCI-T98-0035 Phase
II Randomized Study of Monoclonal Antibody VEGF in Patients With Metastatic
Renal Cell Cancer
Chairperson: James Chung-Yin Yang. Telephone: 301-496-1574. Lead organization:
National Cancer Institute, Division of Clinical Sciences. Age range: 18 and
over.
NCI-98-C-0012,
NCI-T97-0112 Phase
II Study of CAI in Patients With Refractory or Recurrent Ovarian Epithelial,
Fallopian Tube, or Primary Peritoneal Cancer
Chairperson: Elise C. Kohn. Telephone: 301-402-1357. Lead organization: National
Cancer Institute, Division of Clinical Sciences. Age range: 18 and over.
MSKCC-98088,
NCI-G99-1498, MSKCC-98088A(1)
Phase II Study of Thalidomide and Cyclophosphamide in Patients With Recurrent
or Refractory Malignancies
Chairperson: Ira Jay Dunkel. Telephone: 212-639-2153. Lead organization: Memorial
Sloan-Kettering Cancer Center. Age range: not specified.
UARK-94016,
NCI-T94-0176 Phase
II Pilot Study of Suramin for Refractory or Relapsed Multiple Myeloma and Castlemai's
Disease
Chairperson: Nikhil C. Munshi. Telephone: 501-686-8514. Lead organization: University
of Arkansas for Medical Sciences. Age range: over 18.
NCI-96-C-0113F,
NCI-T96-0029N, NCI-MB-386
Phase I/II Pilot Study of Interleukin-12 for AIDS-Associated Kaposi's Sarcoma
Chairperson: Robert Yarchoan. Telephone: 301-496-0328. Lead organization: National
Cancer Institute, Division of Clinical Sciences. Age range: 18 and over.
EUC-DON-9420,
NCI-T94-0033O Phase
II Study of Suramin for Recurrent Primary Adult Brain Tumors
Chairperson: Jeffrey J. Olson. Telephone: 404-778-3091. Lead organization: Department
of Neurosurgery - Emory. Age range: over 15.
JHOC-NABTT-9704
Phase II Study of Penicillamine, Low Copper Diet, and Radiotherapy in Adults
With Newly Diagnosed Glioblastoma
Chairperson: Steven Brem. Telephone: 813-979-3063. Lead organization: Johns
Hopkins Oncology Center. Age range: 18 and over.
Thalidomide
Phase II
NCI-95-C-0178L,
NCI-T95-0038N, NCI-CPB-372
Phase II Randomized Study of Oral Thalidomide in Hormone-Refractory Adenocarcinoma
of the Prostate
Chairperson: Eddie Reed. Telephone: 301-402-1357. Lead organization: National
Cancer Institute, Division of Clinical Sciences. Age range: 18 and over.
NCI-99-C-0102
Phase II Randomized Study of Metastasectomy With or Without Adjuvant Thalidomide
in Patients With Recurrent or Metastatic Colorectal Carcinoma
Chairperson: Steven K. Libutti. Telephone: 301-496-5049. Lead organization:
National Cancer Institute, Division of Clinical Sciences. Age range: 18 and
over.
MSKCC-98088,
NCI-G99-1498, MSKCC-98088A(1)
Phase II Study of Thalidomide and Cyclophosphamide in Patients With Recurrent
or Refractory Malignancies
Chairperson: Ira Jay Dunkel. Telephone: 212-639-2153. Lead organization: Memorial
Sloan-Kettering Cancer Center. Age range: any age.
NCI-96-C-0004E,
NCI-T95-0067N Phase
II Study of Oral Thalidomide in HIV-Associated Kaposi's Sarcoma
Chairperson: Robert Yarchoan. Telephone: 301-496-0328. Lead organization:
National Cancer Institute, Division of Clinical Sciences. Age range: 18 and
over.
RPCI-RP-9809,
NCI-G99-1520 Phase
II Randomized Study of Thalidomide in Patients With Steroid-Dependent or Refractory
Chronic Graft-Versus-Host Disease Following Allogeneic Bone Marrow Transplantation
Chairperson: Barbara Jean Bambach. Telephone: 716-845-2333. Lead organization:
Roswell Park Cancer Institute. Age range: 3 and over.
MDA-ID-98270,
NCI-T98-0074 Phase
II Study of Thalidomide in Patients With Recurrent or Metastatic Squamous
Cell Carcinoma of the Head and Neck
Chairperson: Roy Herbst. Telephone: 713-792-6363. Lead organization: University
of Texas - MD Anderson Cancer Center. Age range: 18 and over.
RTOG-9806
Phase II Study of Conventional Radiotherapy and Thalidomide for Patients With
Supratentorial Glioblastoma Multiforme
Chairperson: Wai-Kwan Alfred Yung. Telephone: 713-794-1285. Lead organization:
Radiation Therapy Oncology Group. Age range: 18 and over.
Matrix
Metalloprotease Inhibitors (MMPs)
Phase
I, II, and III
E-1D95,
AMC-014 Phase II Pilot
Study to Evaluate the Potential Interactions Between Paclitaxel and Protease
Inhibitors in Patients With AIDS-Related Kaposi's Sarcoma.
Chairperson: Jamie Hayden Von Roenn. Telephone: 312-908-9412. Lead organization:
Eastern Cooperative Oncology Group. Age range: 18 and over.
AG-3340-006
Phase III Randomized Study of Matrix Metalloprotease Inhibitor AG3340 in Combination
With Paclitaxel and Carboplatin in Patients With Recurrent or Metastatic Non-Small
Cell Lung Cancer.
Chairperson: Mary Collier. Telephone: 619-622-8036. Lead organization: Agouron
Pharmaceuticals, Inc. Age range: 18 and over.
AG-3340-009
Phase III Randomized Study of Matrix Metalloprotease Inhibitor AG3340 in Combination
With Mitoxantrone and Prednisone in Patients With Hormone Refractory Prostate
Cancer
Chairperson: Mary
Collier. Telephone: 619-622-8036. Lead organization: Agouron Pharmaceuticals,
Inc. Age range: 18 and over.
BAYUMC-098004,
NCI-T98-0054 Phase
I Study of Dendritic Cell Immunotherapy in Patients With Metastatic Melanoma
Chairperson: Joseph
Wayne Fay. Telephone: 214-820-2610. Lead organization: Baylor University Medical
Center. Age range: 18 and over.
Flavopiridol
Phase II
NCI-99-C-0096
Phase II Randomized Study of Flavopiridol With or Without Paclitaxel in Patients
With Esophageal Cancer (Status: Approved - not yet active)
Chairperson:
David S. Schrump. Telephone: 301-496-2127. Lead organization: National Cancer
Institute, Division of Clinical Sciences. Age range: 18 and over.
WCCC-CO-9781,
NCI-T97-0038 Phase
II Study of Flavopiridol in Patients With Metastatic Androgen-Independent
Adenocarcinoma of the Prostate
Chairperson:
George Wilding. Telephone: 608-265-8131. Lead organization: University of
Wisconsin Comprehensive Cancer Center. Age range: not specified.
DFCI-97129,
NCI-T97-0039 Phase
II Study of Flavopiridol in Patients With Relapsed or Refractory Mantle Cell
Lymphoma
Chairperson:
Orion M. Howard. Telephone: 617-632-5618. Lead organization: Dana-Farber Cancer
Institute. Age range: over 18.
JHOC-96110811,
NCI-T96-0101 Phase
II Study of Flavopiridol in Patients With Metastatic or Recurrent Colorectal
Cancer
Chairperson:
Ross C. Donehower. Telephone: 410-955-8838. Lead organization: Johns Hopkins
Oncology Center. Age range: 18 and over.
UCCRC-8548,
NCI-T96-0099 Phase
II Study of Flavopiridol for Recurrent Intermediate and High-Grade Non-Hodgkin’s
Lymphoma and Mantle Cell Lymphoma
Chairperson:
Mark DeMario. Telephone: 773-702-4602. Lead organization: University of Chicago
Cancer Research Center. Age range: 18 and over.
CLB-19805
Phase II Study of
Flavopiridol in Patients With Fludarabine Refractory B-Cell Chronic Lymphocytic
Leukemia
Chairperson:
John C. Byrd. Telephone: 202-782-5746. Lead organization: Cancer and Leukemia
Group B. Age range: 18 and over.
Legend
for Abbreviations
AG = Agouron
Pharmaceuticals, Inc
AMC = AIDS
Malignancy Consortium
BAYUMC = Baylor
University Medical Center
CLB = Cancer
and Leukemia Group B
DFCI = Dana-Farber
Cancer Institute
E = Eastern
Cooperative Oncology Group
EUC-DON =Emory
University – Department of Neurosurgery
JHOC = Johns
Hopkins Oncology Center
MDA = M.D.
Anderson Cancer Center
MSKCC = Memorial
Sloan-Kettering Cancer Center
NABTT = New
Approaches to Brain Tumor Therapy
NCI = National
Cancer Institute
RPCI = Roswell
Park Cancer Institute
RTOG = Radiation
Therapy Oncology Group
RUH-SSH = Rockefeller
University Hospital
UARK = University
of Arkansas for Medical Sciences
UCCRC = University
of Chicago Cancer Research Center
WCCC = University
of Wisconsin Comprehensive Cancer Center